ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ERAS vs DNTH // OPERATING MARGIN

Erasca Inc. (NASDAQ) VS. Dianthus Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ERAS 2 — DNTH 3
■ METRIC PARITY
operating-margins
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ERAS VS. DNTH) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ERAS DNTH SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -30.70% -4.30 DNTH /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -1.82% -2.79% +0.97 ERAS /fcf-yield <GO>
Operating Margin ACTIVE — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — -65.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 26.00 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 4/9 -1.00 DNTH /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 45.3 46.8 -1.50 DNTH /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 1.08 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 20.0x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $5.02B $4.61B $411.2M ERAS /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ERAS REV DNTH REV ERAS GROSS % DNTH GROSS % ERAS FCF DNTH FCF
FY 2025 $394.5M $2.0M — — -$95.6M -$129.2M
FY 2024 $502.8M $6.2M — — -$109.5M -$78.5M
FY 2023 $396.3M $2.8M — — -$101.2M -$37.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ERAS // BETA —
DNTH // BETA 1.08